nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Mitomycin—urinary bladder cancer	0.243	0.379	CbGbCtD
Tolvaptan—CYP3A4—Thiotepa—urinary bladder cancer	0.11	0.172	CbGbCtD
Tolvaptan—ABCB1—Gemcitabine—urinary bladder cancer	0.07	0.109	CbGbCtD
Tolvaptan—ABCB1—Cisplatin—urinary bladder cancer	0.0508	0.0792	CbGbCtD
Tolvaptan—ABCB1—Etoposide—urinary bladder cancer	0.05	0.0778	CbGbCtD
Tolvaptan—AVPR2—urine—urinary bladder cancer	0.0441	0.599	CbGeAlD
Tolvaptan—ABCB1—Doxorubicin—urinary bladder cancer	0.0341	0.0531	CbGbCtD
Tolvaptan—ABCB1—Methotrexate—urinary bladder cancer	0.033	0.0514	CbGbCtD
Tolvaptan—CYP3A4—Etoposide—urinary bladder cancer	0.0299	0.0466	CbGbCtD
Tolvaptan—CYP3A4—Doxorubicin—urinary bladder cancer	0.0204	0.0318	CbGbCtD
Tolvaptan—AVPR2—renal system—urinary bladder cancer	0.0108	0.147	CbGeAlD
Tolvaptan—CYP3A4—urine—urinary bladder cancer	0.00671	0.0912	CbGeAlD
Tolvaptan—ABCB1—prostate gland—urinary bladder cancer	0.0017	0.0232	CbGeAlD
Tolvaptan—CYP3A4—renal system—urinary bladder cancer	0.00164	0.0223	CbGeAlD
Tolvaptan—ABCB1—seminal vesicle—urinary bladder cancer	0.00144	0.0196	CbGeAlD
Tolvaptan—CYP3A4—female reproductive system—urinary bladder cancer	0.00131	0.0179	CbGeAlD
Tolvaptan—ABCB1—epithelium—urinary bladder cancer	0.00125	0.017	CbGeAlD
Tolvaptan—ABCB1—renal system—urinary bladder cancer	0.00116	0.0158	CbGeAlD
Tolvaptan—ABCB1—urethra—urinary bladder cancer	0.00114	0.0155	CbGeAlD
Tolvaptan—AVPR2—Vasopressin regulates renal water homeostasis via Aquaporins—AQP3—urinary bladder cancer	0.0011	0.106	CbGpPWpGaD
Tolvaptan—ABCB1—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00102	0.0979	CbGpPWpGaD
Tolvaptan—Respiratory failure—Methotrexate—urinary bladder cancer	0.000986	0.0036	CcSEcCtD
Tolvaptan—Malnutrition—Thiotepa—urinary bladder cancer	0.000984	0.00359	CcSEcCtD
Tolvaptan—Hyperuricaemia—Epirubicin—urinary bladder cancer	0.000977	0.00356	CcSEcCtD
Tolvaptan—Renal failure—Cisplatin—urinary bladder cancer	0.000971	0.00354	CcSEcCtD
Tolvaptan—Pulmonary embolism—Methotrexate—urinary bladder cancer	0.000969	0.00353	CcSEcCtD
Tolvaptan—AVPR2—Aquaporin-mediated transport—AQP3—urinary bladder cancer	0.00096	0.0923	CbGpPWpGaD
Tolvaptan—Blood bilirubin increased—Epirubicin—urinary bladder cancer	0.000958	0.00349	CcSEcCtD
Tolvaptan—Nausea—Mitomycin—urinary bladder cancer	0.000949	0.00346	CcSEcCtD
Tolvaptan—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000939	0.00342	CcSEcCtD
Tolvaptan—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000935	0.00341	CcSEcCtD
Tolvaptan—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000932	0.0034	CcSEcCtD
Tolvaptan—ABCB1—female reproductive system—urinary bladder cancer	0.00093	0.0127	CbGeAlD
Tolvaptan—Blood uric acid increased—Epirubicin—urinary bladder cancer	0.000923	0.00337	CcSEcCtD
Tolvaptan—Pulmonary embolism—Epirubicin—urinary bladder cancer	0.000907	0.0033	CcSEcCtD
Tolvaptan—Hyperuricaemia—Doxorubicin—urinary bladder cancer	0.000904	0.0033	CcSEcCtD
Tolvaptan—Hyperkalaemia—Epirubicin—urinary bladder cancer	0.000891	0.00325	CcSEcCtD
Tolvaptan—Renal failure—Etoposide—urinary bladder cancer	0.000889	0.00324	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Doxorubicin—urinary bladder cancer	0.000887	0.00323	CcSEcCtD
Tolvaptan—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.000883	0.00322	CcSEcCtD
Tolvaptan—Urine output increased—Methotrexate—urinary bladder cancer	0.000876	0.00319	CcSEcCtD
Tolvaptan—Ecchymosis—Methotrexate—urinary bladder cancer	0.000876	0.00319	CcSEcCtD
Tolvaptan—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000875	0.00319	CcSEcCtD
Tolvaptan—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000871	0.00318	CcSEcCtD
Tolvaptan—Urethral disorder—Cisplatin—urinary bladder cancer	0.000869	0.00317	CcSEcCtD
Tolvaptan—Angiopathy—Gemcitabine—urinary bladder cancer	0.000863	0.00315	CcSEcCtD
Tolvaptan—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000859	0.00313	CcSEcCtD
Tolvaptan—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000857	0.00312	CcSEcCtD
Tolvaptan—Blood uric acid increased—Doxorubicin—urinary bladder cancer	0.000854	0.00311	CcSEcCtD
Tolvaptan—ABCB1—vagina—urinary bladder cancer	0.000842	0.0114	CbGeAlD
Tolvaptan—Pulmonary embolism—Doxorubicin—urinary bladder cancer	0.000839	0.00306	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000832	0.00303	CcSEcCtD
Tolvaptan—Hyperkalaemia—Doxorubicin—urinary bladder cancer	0.000824	0.003	CcSEcCtD
Tolvaptan—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000823	0.003	CcSEcCtD
Tolvaptan—Ecchymosis—Epirubicin—urinary bladder cancer	0.00082	0.00299	CcSEcCtD
Tolvaptan—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000802	0.00292	CcSEcCtD
Tolvaptan—Polyuria—Methotrexate—urinary bladder cancer	0.000801	0.00292	CcSEcCtD
Tolvaptan—Immune system disorder—Cisplatin—urinary bladder cancer	0.000801	0.00292	CcSEcCtD
Tolvaptan—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000799	0.00291	CcSEcCtD
Tolvaptan—Urethral disorder—Etoposide—urinary bladder cancer	0.000796	0.0029	CcSEcCtD
Tolvaptan—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000788	0.00287	CcSEcCtD
Tolvaptan—Skin disorder—Thiotepa—urinary bladder cancer	0.00078	0.00284	CcSEcCtD
Tolvaptan—Malnutrition—Cisplatin—urinary bladder cancer	0.000772	0.00281	CcSEcCtD
Tolvaptan—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000768	0.0028	CcSEcCtD
Tolvaptan—Anorexia—Thiotepa—urinary bladder cancer	0.000766	0.00279	CcSEcCtD
Tolvaptan—Ecchymosis—Doxorubicin—urinary bladder cancer	0.000758	0.00276	CcSEcCtD
Tolvaptan—Cardiac disorder—Etoposide—urinary bladder cancer	0.000754	0.00275	CcSEcCtD
Tolvaptan—Malaise—Gemcitabine—urinary bladder cancer	0.000747	0.00272	CcSEcCtD
Tolvaptan—Angiopathy—Etoposide—urinary bladder cancer	0.000737	0.00269	CcSEcCtD
Tolvaptan—Immune system disorder—Etoposide—urinary bladder cancer	0.000734	0.00267	CcSEcCtD
Tolvaptan—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000732	0.00267	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000718	0.00262	CcSEcCtD
Tolvaptan—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.000716	0.00261	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.0007	0.00255	CcSEcCtD
Tolvaptan—Decreased appetite—Thiotepa—urinary bladder cancer	0.000698	0.00255	CcSEcCtD
Tolvaptan—Discomfort—Gemcitabine—urinary bladder cancer	0.000696	0.00254	CcSEcCtD
Tolvaptan—Malaise—Cisplatin—urinary bladder cancer	0.000696	0.00254	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000693	0.00253	CcSEcCtD
Tolvaptan—Dysgeusia—Etoposide—urinary bladder cancer	0.000692	0.00252	CcSEcCtD
Tolvaptan—Renal impairment—Epirubicin—urinary bladder cancer	0.000691	0.00252	CcSEcCtD
Tolvaptan—Constipation—Thiotepa—urinary bladder cancer	0.000687	0.0025	CcSEcCtD
Tolvaptan—Discomfort—Fluorouracil—urinary bladder cancer	0.000685	0.0025	CcSEcCtD
Tolvaptan—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000676	0.00246	CcSEcCtD
Tolvaptan—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000674	0.00246	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000671	0.00245	CcSEcCtD
Tolvaptan—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000664	0.00242	CcSEcCtD
Tolvaptan—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000663	0.00242	CcSEcCtD
Tolvaptan—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000662	0.00241	CcSEcCtD
Tolvaptan—Hyponatraemia—Epirubicin—urinary bladder cancer	0.000661	0.00241	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000658	0.0024	CcSEcCtD
Tolvaptan—Skin disorder—Gemcitabine—urinary bladder cancer	0.000656	0.00239	CcSEcCtD
Tolvaptan—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000656	0.00239	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000652	0.00238	CcSEcCtD
Tolvaptan—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000651	0.00238	CcSEcCtD
Tolvaptan—Discomfort—Cisplatin—urinary bladder cancer	0.000649	0.00237	CcSEcCtD
Tolvaptan—Anorexia—Gemcitabine—urinary bladder cancer	0.000644	0.00235	CcSEcCtD
Tolvaptan—Renal impairment—Doxorubicin—urinary bladder cancer	0.00064	0.00233	CcSEcCtD
Tolvaptan—Malaise—Etoposide—urinary bladder cancer	0.000637	0.00232	CcSEcCtD
Tolvaptan—Breast disorder—Methotrexate—urinary bladder cancer	0.000635	0.00232	CcSEcCtD
Tolvaptan—Body temperature increased—Thiotepa—urinary bladder cancer	0.000635	0.00231	CcSEcCtD
Tolvaptan—Anorexia—Fluorouracil—urinary bladder cancer	0.000633	0.00231	CcSEcCtD
Tolvaptan—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00063	0.0023	CcSEcCtD
Tolvaptan—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.000627	0.0603	CbGpPWpGaD
Tolvaptan—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000624	0.00227	CcSEcCtD
Tolvaptan—Loss of consciousness—Etoposide—urinary bladder cancer	0.000621	0.00227	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000621	0.00226	CcSEcCtD
Tolvaptan—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000618	0.00225	CcSEcCtD
Tolvaptan—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000616	0.00225	CcSEcCtD
Tolvaptan—Dehydration—Epirubicin—urinary bladder cancer	0.000612	0.00223	CcSEcCtD
Tolvaptan—Skin disorder—Cisplatin—urinary bladder cancer	0.000612	0.00223	CcSEcCtD
Tolvaptan—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000611	0.00223	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000609	0.00222	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000601	0.00219	CcSEcCtD
Tolvaptan—Anorexia—Cisplatin—urinary bladder cancer	0.0006	0.00219	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000598	0.00218	CcSEcCtD
Tolvaptan—Discomfort—Etoposide—urinary bladder cancer	0.000595	0.00217	CcSEcCtD
Tolvaptan—Breast disorder—Epirubicin—urinary bladder cancer	0.000595	0.00217	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000593	0.00216	CcSEcCtD
Tolvaptan—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000592	0.00216	CcSEcCtD
Tolvaptan—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000587	0.00214	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000583	0.00213	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.00058	0.00212	CcSEcCtD
Tolvaptan—Constipation—Gemcitabine—urinary bladder cancer	0.000578	0.00211	CcSEcCtD
Tolvaptan—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000577	0.00211	CcSEcCtD
Tolvaptan—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000577	0.0021	CcSEcCtD
Tolvaptan—Asthenia—Thiotepa—urinary bladder cancer	0.000576	0.0021	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000574	0.00209	CcSEcCtD
Tolvaptan—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.00057	0.00208	CcSEcCtD
Tolvaptan—Pruritus—Thiotepa—urinary bladder cancer	0.000568	0.00207	CcSEcCtD
Tolvaptan—Dehydration—Doxorubicin—urinary bladder cancer	0.000566	0.00206	CcSEcCtD
Tolvaptan—Skin disorder—Etoposide—urinary bladder cancer	0.00056	0.00204	CcSEcCtD
Tolvaptan—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000557	0.00203	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000556	0.00203	CcSEcCtD
Tolvaptan—Breast disorder—Doxorubicin—urinary bladder cancer	0.00055	0.00201	CcSEcCtD
Tolvaptan—Anorexia—Etoposide—urinary bladder cancer	0.00055	0.002	CcSEcCtD
Tolvaptan—Diarrhoea—Thiotepa—urinary bladder cancer	0.00055	0.002	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000548	0.002	CcSEcCtD
Tolvaptan—Decreased appetite—Cisplatin—urinary bladder cancer	0.000547	0.002	CcSEcCtD
Tolvaptan—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000547	0.002	CcSEcCtD
Tolvaptan—ABCB1—lymph node—urinary bladder cancer	0.000544	0.0074	CbGeAlD
Tolvaptan—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000544	0.00198	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000537	0.00196	CcSEcCtD
Tolvaptan—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000534	0.00195	CcSEcCtD
Tolvaptan—Renal failure—Methotrexate—urinary bladder cancer	0.000533	0.00194	CcSEcCtD
Tolvaptan—Dizziness—Thiotepa—urinary bladder cancer	0.000531	0.00194	CcSEcCtD
Tolvaptan—Pollakiuria—Epirubicin—urinary bladder cancer	0.000525	0.00192	CcSEcCtD
Tolvaptan—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000525	0.00191	CcSEcCtD
Tolvaptan—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000519	0.00189	CcSEcCtD
Tolvaptan—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000513	0.00187	CcSEcCtD
Tolvaptan—Headache—Thiotepa—urinary bladder cancer	0.000503	0.00183	CcSEcCtD
Tolvaptan—Decreased appetite—Etoposide—urinary bladder cancer	0.000502	0.00183	CcSEcCtD
Tolvaptan—Renal failure—Epirubicin—urinary bladder cancer	0.000498	0.00182	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000498	0.00182	CcSEcCtD
Tolvaptan—Body temperature increased—Cisplatin—urinary bladder cancer	0.000498	0.00181	CcSEcCtD
Tolvaptan—Constipation—Etoposide—urinary bladder cancer	0.000493	0.0018	CcSEcCtD
Tolvaptan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000489	0.00178	CcSEcCtD
Tolvaptan—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000486	0.00177	CcSEcCtD
Tolvaptan—Asthenia—Gemcitabine—urinary bladder cancer	0.000485	0.00177	CcSEcCtD
Tolvaptan—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00048	0.00175	CcSEcCtD
Tolvaptan—Pruritus—Gemcitabine—urinary bladder cancer	0.000478	0.00174	CcSEcCtD
Tolvaptan—Nausea—Thiotepa—urinary bladder cancer	0.000477	0.00174	CcSEcCtD
Tolvaptan—Urethral disorder—Methotrexate—urinary bladder cancer	0.000477	0.00174	CcSEcCtD
Tolvaptan—Feeling abnormal—Etoposide—urinary bladder cancer	0.000475	0.00173	CcSEcCtD
Tolvaptan—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000475	0.00173	CcSEcCtD
Tolvaptan—Pruritus—Fluorouracil—urinary bladder cancer	0.00047	0.00171	CcSEcCtD
Tolvaptan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000464	0.00169	CcSEcCtD
Tolvaptan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000462	0.00169	CcSEcCtD
Tolvaptan—Renal failure—Doxorubicin—urinary bladder cancer	0.000461	0.00168	CcSEcCtD
Tolvaptan—Body temperature increased—Etoposide—urinary bladder cancer	0.000456	0.00166	CcSEcCtD
Tolvaptan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000455	0.00166	CcSEcCtD
Tolvaptan—Asthenia—Cisplatin—urinary bladder cancer	0.000452	0.00165	CcSEcCtD
Tolvaptan—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000451	0.00165	CcSEcCtD
Tolvaptan—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00045	0.00164	CcSEcCtD
Tolvaptan—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000447	0.00163	CcSEcCtD
Tolvaptan—Urethral disorder—Epirubicin—urinary bladder cancer	0.000446	0.00163	CcSEcCtD
Tolvaptan—Angiopathy—Methotrexate—urinary bladder cancer	0.000441	0.00161	CcSEcCtD
Tolvaptan—Immune system disorder—Methotrexate—urinary bladder cancer	0.000439	0.0016	CcSEcCtD
Tolvaptan—Dizziness—Fluorouracil—urinary bladder cancer	0.000439	0.0016	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000438	0.0016	CcSEcCtD
Tolvaptan—Diarrhoea—Cisplatin—urinary bladder cancer	0.000431	0.00157	CcSEcCtD
Tolvaptan—Hypersensitivity—Etoposide—urinary bladder cancer	0.000425	0.00155	CcSEcCtD
Tolvaptan—Malnutrition—Methotrexate—urinary bladder cancer	0.000423	0.00154	CcSEcCtD
Tolvaptan—Headache—Gemcitabine—urinary bladder cancer	0.000423	0.00154	CcSEcCtD
Tolvaptan—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000422	0.00154	CcSEcCtD
Tolvaptan—Headache—Fluorouracil—urinary bladder cancer	0.000416	0.00152	CcSEcCtD
Tolvaptan—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000416	0.00152	CcSEcCtD
Tolvaptan—Dysgeusia—Methotrexate—urinary bladder cancer	0.000415	0.00151	CcSEcCtD
Tolvaptan—Asthenia—Etoposide—urinary bladder cancer	0.000414	0.00151	CcSEcCtD
Tolvaptan—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000414	0.00151	CcSEcCtD
Tolvaptan—Angiopathy—Epirubicin—urinary bladder cancer	0.000413	0.00151	CcSEcCtD
Tolvaptan—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000413	0.00151	CcSEcCtD
Tolvaptan—Immune system disorder—Epirubicin—urinary bladder cancer	0.000411	0.0015	CcSEcCtD
Tolvaptan—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00041	0.0015	CcSEcCtD
Tolvaptan—Pruritus—Etoposide—urinary bladder cancer	0.000408	0.00149	CcSEcCtD
Tolvaptan—Nausea—Gemcitabine—urinary bladder cancer	0.000401	0.00146	CcSEcCtD
Tolvaptan—Malnutrition—Epirubicin—urinary bladder cancer	0.000396	0.00144	CcSEcCtD
Tolvaptan—Diarrhoea—Etoposide—urinary bladder cancer	0.000395	0.00144	CcSEcCtD
Tolvaptan—Nausea—Fluorouracil—urinary bladder cancer	0.000395	0.00144	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000393	0.00143	CcSEcCtD
Tolvaptan—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000391	0.00143	CcSEcCtD
Tolvaptan—Dysgeusia—Epirubicin—urinary bladder cancer	0.000388	0.00141	CcSEcCtD
Tolvaptan—Angiopathy—Doxorubicin—urinary bladder cancer	0.000382	0.00139	CcSEcCtD
Tolvaptan—Malaise—Methotrexate—urinary bladder cancer	0.000382	0.00139	CcSEcCtD
Tolvaptan—Dizziness—Etoposide—urinary bladder cancer	0.000382	0.00139	CcSEcCtD
Tolvaptan—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00038	0.00139	CcSEcCtD
Tolvaptan—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00038	0.00138	CcSEcCtD
Tolvaptan—Nausea—Cisplatin—urinary bladder cancer	0.000374	0.00136	CcSEcCtD
Tolvaptan—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000368	0.00134	CcSEcCtD
Tolvaptan—Malnutrition—Doxorubicin—urinary bladder cancer	0.000367	0.00134	CcSEcCtD
Tolvaptan—Headache—Etoposide—urinary bladder cancer	0.000361	0.00132	CcSEcCtD
Tolvaptan—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000359	0.00131	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000358	0.00131	CcSEcCtD
Tolvaptan—Malaise—Epirubicin—urinary bladder cancer	0.000357	0.0013	CcSEcCtD
Tolvaptan—Discomfort—Methotrexate—urinary bladder cancer	0.000356	0.0013	CcSEcCtD
Tolvaptan—Syncope—Epirubicin—urinary bladder cancer	0.000355	0.0013	CcSEcCtD
Tolvaptan—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000348	0.00127	CcSEcCtD
Tolvaptan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000346	0.00126	CcSEcCtD
Tolvaptan—Nausea—Etoposide—urinary bladder cancer	0.000343	0.00125	CcSEcCtD
Tolvaptan—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00034	0.00124	CcSEcCtD
Tolvaptan—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000339	0.00124	CcSEcCtD
Tolvaptan—Skin disorder—Methotrexate—urinary bladder cancer	0.000336	0.00122	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000335	0.00122	CcSEcCtD
Tolvaptan—Discomfort—Epirubicin—urinary bladder cancer	0.000333	0.00122	CcSEcCtD
Tolvaptan—Malaise—Doxorubicin—urinary bladder cancer	0.000331	0.00121	CcSEcCtD
Tolvaptan—Dry mouth—Epirubicin—urinary bladder cancer	0.00033	0.0012	CcSEcCtD
Tolvaptan—Anorexia—Methotrexate—urinary bladder cancer	0.000329	0.0012	CcSEcCtD
Tolvaptan—Syncope—Doxorubicin—urinary bladder cancer	0.000329	0.0012	CcSEcCtD
Tolvaptan—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000328	0.0315	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000323	0.00118	CcSEcCtD
Tolvaptan—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000322	0.00117	CcSEcCtD
Tolvaptan—Shock—Epirubicin—urinary bladder cancer	0.000318	0.00116	CcSEcCtD
Tolvaptan—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000317	0.00116	CcSEcCtD
Tolvaptan—Skin disorder—Epirubicin—urinary bladder cancer	0.000314	0.00115	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00031	0.00113	CcSEcCtD
Tolvaptan—Discomfort—Doxorubicin—urinary bladder cancer	0.000308	0.00112	CcSEcCtD
Tolvaptan—Anorexia—Epirubicin—urinary bladder cancer	0.000308	0.00112	CcSEcCtD
Tolvaptan—Dry mouth—Doxorubicin—urinary bladder cancer	0.000305	0.00111	CcSEcCtD
Tolvaptan—Decreased appetite—Methotrexate—urinary bladder cancer	0.0003	0.0011	CcSEcCtD
Tolvaptan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000299	0.00109	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000298	0.00109	CcSEcCtD
Tolvaptan—Shock—Doxorubicin—urinary bladder cancer	0.000294	0.00107	CcSEcCtD
Tolvaptan—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000293	0.00107	CcSEcCtD
Tolvaptan—Skin disorder—Doxorubicin—urinary bladder cancer	0.000291	0.00106	CcSEcCtD
Tolvaptan—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00029	0.0279	CbGpPWpGaD
Tolvaptan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000288	0.0277	CbGpPWpGaD
Tolvaptan—Anorexia—Doxorubicin—urinary bladder cancer	0.000285	0.00104	CcSEcCtD
Tolvaptan—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000285	0.00104	CcSEcCtD
Tolvaptan—Decreased appetite—Epirubicin—urinary bladder cancer	0.000281	0.00102	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000279	0.00102	CcSEcCtD
Tolvaptan—Constipation—Epirubicin—urinary bladder cancer	0.000277	0.00101	CcSEcCtD
Tolvaptan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000273	0.000996	CcSEcCtD
Tolvaptan—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000267	0.000972	CcSEcCtD
Tolvaptan—AVPR2—Arf6 trafficking events—CDH1—urinary bladder cancer	0.000262	0.0252	CbGpPWpGaD
Tolvaptan—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00026	0.000948	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000258	0.000942	CcSEcCtD
Tolvaptan—Constipation—Doxorubicin—urinary bladder cancer	0.000256	0.000933	CcSEcCtD
Tolvaptan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000256	0.000932	CcSEcCtD
Tolvaptan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000255	0.000928	CcSEcCtD
Tolvaptan—Asthenia—Methotrexate—urinary bladder cancer	0.000248	0.000904	CcSEcCtD
Tolvaptan—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000247	0.000899	CcSEcCtD
Tolvaptan—Pruritus—Methotrexate—urinary bladder cancer	0.000244	0.000891	CcSEcCtD
Tolvaptan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000238	0.000869	CcSEcCtD
Tolvaptan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000237	0.000862	CcSEcCtD
Tolvaptan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000236	0.000862	CcSEcCtD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000235	0.0226	CbGpPWpGaD
Tolvaptan—Asthenia—Epirubicin—urinary bladder cancer	0.000232	0.000846	CcSEcCtD
Tolvaptan—Pruritus—Epirubicin—urinary bladder cancer	0.000229	0.000834	CcSEcCtD
Tolvaptan—Dizziness—Methotrexate—urinary bladder cancer	0.000229	0.000833	CcSEcCtD
Tolvaptan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000221	0.000807	CcSEcCtD
Tolvaptan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00022	0.000804	CcSEcCtD
Tolvaptan—Headache—Methotrexate—urinary bladder cancer	0.000216	0.000789	CcSEcCtD
Tolvaptan—Asthenia—Doxorubicin—urinary bladder cancer	0.000215	0.000783	CcSEcCtD
Tolvaptan—Dizziness—Epirubicin—urinary bladder cancer	0.000214	0.00078	CcSEcCtD
Tolvaptan—Pruritus—Doxorubicin—urinary bladder cancer	0.000212	0.000772	CcSEcCtD
Tolvaptan—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000207	0.0199	CbGpPWpGaD
Tolvaptan—Nausea—Methotrexate—urinary bladder cancer	0.000205	0.000748	CcSEcCtD
Tolvaptan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000205	0.000746	CcSEcCtD
Tolvaptan—Headache—Epirubicin—urinary bladder cancer	0.000203	0.000739	CcSEcCtD
Tolvaptan—Dizziness—Doxorubicin—urinary bladder cancer	0.000198	0.000721	CcSEcCtD
Tolvaptan—Nausea—Epirubicin—urinary bladder cancer	0.000192	0.0007	CcSEcCtD
Tolvaptan—Headache—Doxorubicin—urinary bladder cancer	0.000187	0.000683	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000183	0.0176	CbGpPWpGaD
Tolvaptan—Nausea—Doxorubicin—urinary bladder cancer	0.000178	0.000648	CcSEcCtD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000177	0.0171	CbGpPWpGaD
Tolvaptan—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000148	0.0142	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000133	0.0127	CbGpPWpGaD
Tolvaptan—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000127	0.0122	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000113	0.0108	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000111	0.0107	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000108	0.0104	CbGpPWpGaD
Tolvaptan—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	9.7e-05	0.00932	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	9.13e-05	0.00878	CbGpPWpGaD
Tolvaptan—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	9.1e-05	0.00875	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	8.19e-05	0.00787	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	7.3e-05	0.00701	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	6.91e-05	0.00664	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—CXCL8—urinary bladder cancer	6.86e-05	0.00659	CbGpPWpGaD
Tolvaptan—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	6.78e-05	0.00652	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	6.22e-05	0.00597	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	6.13e-05	0.00589	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	5.89e-05	0.00566	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	5.89e-05	0.00566	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	5.81e-05	0.00559	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	5.39e-05	0.00518	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	5.32e-05	0.00511	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HDAC4—urinary bladder cancer	5.23e-05	0.00503	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HDAC4—urinary bladder cancer	5.19e-05	0.00499	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	5.05e-05	0.00486	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	4.91e-05	0.00472	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	4.85e-05	0.00466	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	4.79e-05	0.0046	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.63e-05	0.00445	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	4.6e-05	0.00442	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	4.57e-05	0.0044	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GLI1—urinary bladder cancer	4.38e-05	0.00421	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GLI1—urinary bladder cancer	4.35e-05	0.00418	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	4.32e-05	0.00416	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	4.32e-05	0.00415	CbGpPWpGaD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	4.18e-05	0.00402	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	3.85e-05	0.0037	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	3.83e-05	0.00368	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	3.83e-05	0.00368	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	3.67e-05	0.00353	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—CXCL8—urinary bladder cancer	3.53e-05	0.00339	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CXCL8—urinary bladder cancer	3.5e-05	0.00337	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	3.49e-05	0.00336	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.42e-05	0.00328	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	3.23e-05	0.0031	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	3.18e-05	0.00306	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	3.08e-05	0.00296	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RBX1—urinary bladder cancer	3e-05	0.00289	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RBX1—urinary bladder cancer	2.98e-05	0.00287	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	2.89e-05	0.00278	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TSC1—urinary bladder cancer	2.82e-05	0.00271	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TSC1—urinary bladder cancer	2.8e-05	0.00269	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—JAG1—urinary bladder cancer	2.69e-05	0.00258	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—JAG1—urinary bladder cancer	2.67e-05	0.00256	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	2.64e-05	0.00253	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	2.61e-05	0.00251	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	2.58e-05	0.00248	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	2.52e-05	0.00243	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	2.52e-05	0.00242	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	2.5e-05	0.00241	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	2.45e-05	0.00236	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	2.41e-05	0.00231	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—RHOA—urinary bladder cancer	2.27e-05	0.00218	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—RHOA—urinary bladder cancer	2.26e-05	0.00217	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—S100B—urinary bladder cancer	2.18e-05	0.00209	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—S100B—urinary bladder cancer	2.16e-05	0.00208	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.13e-05	0.00205	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—RHOA—urinary bladder cancer	2.06e-05	0.00198	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.06e-05	0.00198	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—RHOA—urinary bladder cancer	2.05e-05	0.00197	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.99e-05	0.00192	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.98e-05	0.0019	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NCOR1—urinary bladder cancer	1.96e-05	0.00188	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NCOR1—urinary bladder cancer	1.94e-05	0.00187	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—IL2—urinary bladder cancer	1.91e-05	0.00183	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—IL2—urinary bladder cancer	1.89e-05	0.00182	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	1.89e-05	0.00181	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	1.88e-05	0.0018	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	1.87e-05	0.0018	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	1.84e-05	0.00176	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	1.81e-05	0.00174	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.8e-05	0.00173	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	1.74e-05	0.00167	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL2—urinary bladder cancer	1.73e-05	0.00166	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	1.73e-05	0.00166	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TERT—urinary bladder cancer	1.72e-05	0.00166	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL2—urinary bladder cancer	1.72e-05	0.00165	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TERT—urinary bladder cancer	1.71e-05	0.00165	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	1.71e-05	0.00164	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.64e-05	0.00157	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTO2—urinary bladder cancer	1.64e-05	0.00157	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NAT1—urinary bladder cancer	1.64e-05	0.00157	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.62e-05	0.00156	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	1.59e-05	0.00153	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FGFR3—urinary bladder cancer	1.58e-05	0.00152	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	1.57e-05	0.00151	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FGFR3—urinary bladder cancer	1.57e-05	0.00151	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ESR1—urinary bladder cancer	1.54e-05	0.00148	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ESR1—urinary bladder cancer	1.53e-05	0.00147	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.5e-05	0.00144	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.39e-05	0.00134	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.37e-05	0.00132	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.35e-05	0.00129	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.35e-05	0.00129	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.34e-05	0.00129	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CREBBP—urinary bladder cancer	1.34e-05	0.00129	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IGF1—urinary bladder cancer	1.33e-05	0.00128	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.32e-05	0.00127	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IGF1—urinary bladder cancer	1.32e-05	0.00127	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—EGFR—urinary bladder cancer	1.31e-05	0.00126	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.27e-05	0.00122	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.25e-05	0.0012	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—KRAS—urinary bladder cancer	1.24e-05	0.00119	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.24e-05	0.00119	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.22e-05	0.00117	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.21e-05	0.00117	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RHOA—urinary bladder cancer	1.21e-05	0.00116	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.17e-05	0.00113	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.17e-05	0.00112	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.13e-05	0.00108	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ERBB2—urinary bladder cancer	1.12e-05	0.00108	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.12e-05	0.00107	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.09e-05	0.00104	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.07e-05	0.00103	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.06e-05	0.00102	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.06e-05	0.00102	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CXCL8—urinary bladder cancer	1.06e-05	0.00102	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—HRAS—urinary bladder cancer	1.06e-05	0.00101	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL2—urinary bladder cancer	1.02e-05	0.000983	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL2—urinary bladder cancer	1.02e-05	0.000976	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.01e-05	0.000969	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.01e-05	0.000969	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCND1—urinary bladder cancer	9.97e-06	0.000958	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TYMP—urinary bladder cancer	9.91e-06	0.000952	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCND1—urinary bladder cancer	9.9e-06	0.000951	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	9.72e-06	0.000935	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MMP9—urinary bladder cancer	9.68e-06	0.00093	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.64e-06	0.000927	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTEN—urinary bladder cancer	9.62e-06	0.000925	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MMP9—urinary bladder cancer	9.61e-06	0.000923	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CDKN1A—urinary bladder cancer	9.57e-06	0.00092	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTEN—urinary bladder cancer	9.55e-06	0.000918	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	9.51e-06	0.000914	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	9.22e-06	0.000886	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EP300—urinary bladder cancer	9.18e-06	0.000882	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EP300—urinary bladder cancer	9.11e-06	0.000876	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	9.06e-06	0.000871	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	8.98e-06	0.000864	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NAT2—urinary bladder cancer	8.96e-06	0.000861	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SRC—urinary bladder cancer	8.92e-06	0.000858	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SRC—urinary bladder cancer	8.86e-06	0.000851	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	8.3e-06	0.000798	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MYC—urinary bladder cancer	8e-06	0.000768	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	7.99e-06	0.000768	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MYC—urinary bladder cancer	7.94e-06	0.000763	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	7.84e-06	0.000753	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EGFR—urinary bladder cancer	7.82e-06	0.000752	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EGFR—urinary bladder cancer	7.76e-06	0.000746	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—RRM2—urinary bladder cancer	7.74e-06	0.000744	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	7.64e-06	0.000734	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KRAS—urinary bladder cancer	7.39e-06	0.00071	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KRAS—urinary bladder cancer	7.33e-06	0.000705	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—HPGDS—urinary bladder cancer	7.16e-06	0.000689	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ENO2—urinary bladder cancer	7.16e-06	0.000689	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTT1—urinary bladder cancer	6.95e-06	0.000668	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TP53—urinary bladder cancer	6.57e-06	0.000631	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TP53—urinary bladder cancer	6.52e-06	0.000627	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.51e-06	0.000625	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HRAS—urinary bladder cancer	6.28e-06	0.000604	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HRAS—urinary bladder cancer	6.23e-06	0.000599	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TYMP—urinary bladder cancer	6.1e-06	0.000587	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NQO1—urinary bladder cancer	5.77e-06	0.000555	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NAT2—urinary bladder cancer	5.52e-06	0.000531	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.82e-06	0.000463	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—RRM2—urinary bladder cancer	4.77e-06	0.000458	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.48e-06	0.00043	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.43e-06	0.000425	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.43e-06	0.000425	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	4.41e-06	0.000424	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ENO2—urinary bladder cancer	4.41e-06	0.000424	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	4.28e-06	0.000411	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.24e-06	0.000407	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.16e-06	0.0004	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.91e-06	0.000376	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NQO1—urinary bladder cancer	3.56e-06	0.000342	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.17e-06	0.000305	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.05e-06	0.000293	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.97e-06	0.000285	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.76e-06	0.000265	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.73e-06	0.000262	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.73e-06	0.000262	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.61e-06	0.000251	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.56e-06	0.000246	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.5e-06	0.00024	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	2.41e-06	0.000232	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.18e-06	0.000209	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—EP300—urinary bladder cancer	2.08e-06	0.000199	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.95e-06	0.000188	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.88e-06	0.00018	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.54e-06	0.000148	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.34e-06	0.000129	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.28e-06	0.000123	CbGpPWpGaD
